Analyst Reco. Lipocine Inc.

Equities

LPCN

US53630X2036

Market Closed - Nasdaq Other stock markets 02:00:00 07/05/2024 am IST			5-day change	1st Jan Change
4.92 ^USD	+5.13%		+4.02%	+76.34%

01/05	Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154	CI
12/04	Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LIPOCINE : HC Wainwright Adjusts Lipocine's Price Target to $3.50 From $2.50, Keeps Buy Rating	26/21/26	MT
LIPOCINE : Cantor Fitzgerald Starts Lipocine at Overweight With $3 Price Target	24/21/24	MT
LIPOCINE : Ladenburg Thalmann Adjusts Lipocine's Price Target to $2.50 From $3, Maintains Buy Rating	27/21/27	MT
LIPOCINE : HC Wainwright Adjusts Price Target for Lipocine to $2.50 From $3, Maintains Buy Rating	27/21/27	MT
LIPOCINE : Ladenburg Thalmann Upgrades Lipocine to Buy From Neutral, $3 Price Target	10/20/10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW